Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04640623




Registration number
NCT04640623
Ethics application status
Date submitted
20/11/2020
Date registered
23/11/2020
Date last updated
22/05/2024

Titles & IDs
Public title
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Scientific title
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Secondary ID [1] 0 0
2020-002646-16
Secondary ID [2] 0 0
CR108921
Universal Trial Number (UTN)
Trial acronym
SunRISe-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bladder - transitional cell cancer
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TAR-200
Other interventions - Cetrelimab

Experimental: Cohort 1: TAR-200 and Cetrelimab - TAR-200 is placed into the bladder through a urinary placement catheter in participants with carcinoma in situ (CIS), with or without papillary disease, on Day 0 and will be dosed every 3 weeks (Q3W) for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2). In addition, Cetrelimab will be dosed Q3W through Week 78 (18 months).

Experimental: Cohort 2: TAR-200 - TAR-200 is placed into the bladder through a urinary placement catheter in participants with CIS, with or without papillary disease, on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).

Experimental: Cohort 3: Cetrelimab - Participants with CIS, with or without papillary disease, will receive Cetrelimab which will be dosed Q3W through Week 78 (18 months).

Experimental: Cohort 4: TAR-200 (Participants with Papillary Disease only) - TAR-200 is placed into the bladder through a urinary placement catheter in participants with papillary disease only, on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).


Treatment: Drugs: TAR-200
TAR-200 will be administered transuretherally.

Other interventions: Cetrelimab
Cetrelimab will be administered.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Cohort 1, 2, and 3: Overall Complete Response (CR) Rate
Timepoint [1] 0 0
Up to 5 years
Primary outcome [2] 0 0
Cohort 4: Disease-free Survival (DFS)
Timepoint [2] 0 0
Up to 5 years
Secondary outcome [1] 0 0
Cohort 1, 2, and 3: Duration of Response (DOR)
Timepoint [1] 0 0
Up to 5 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to 5 years
Secondary outcome [3] 0 0
Cohort 1, 2, and 4: Concentrations of Gemcitabine and 2',2' difluorodeoxyuridine (dFdU) in Urine and Plasma
Timepoint [3] 0 0
Up to Week 21
Secondary outcome [4] 0 0
Cohort 1 and 3: Serum Concentration of Anti-cetrelimab Antibodies
Timepoint [4] 0 0
Predose, up to 3 years
Secondary outcome [5] 0 0
Number of Participants with Anti-cetrelimab Antibodies
Timepoint [5] 0 0
Predose, up to 3 years
Secondary outcome [6] 0 0
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ) -C30 Scores
Timepoint [6] 0 0
Baseline, up to 3 years and 4 months
Secondary outcome [7] 0 0
Change from Baseline in EORTC QLQ- Non-Muscle-Invasive Bladder Cancer (NMIBC) 24 Scores
Timepoint [7] 0 0
Baseline, up to 3 years and 4 months
Secondary outcome [8] 0 0
Number of Participants with Adverse Events (AEs) by Severity Grades
Timepoint [8] 0 0
Up to 5 years

Eligibility
Key inclusion criteria
- Histologically confirmed diagnosis of persistent or recurrent high-risk non-muscle
invasive bladder cancer (HR-NMIBC), (carcinoma in situ [CIS] or tumor in situ [Tis]),
with or without papillary disease (T1, high-grade Ta) or papillary disease only
(high-grade Ta or any T1 and absence of CIS), within 12 months of completion of the
last dose of Bacillus Calmette-Guerin (BCG) therapy, in participants who have received
adequate BCG. Mixed histology tumors are allowed if urothelial differentiation
(transitional cell histology) is predominant. However, the presence of neuroendocrine,
micropapillary, signet ring cell, plasmacytoid, or sarcomatoid features will make a
participant ineligible. For participants with lamina propria invasion (T1) on the
screening biopsy/ transurethral resection of bladder tumor (TURBT), muscularis propria
must be present in order to rule out Muscle Invasive Bladder Cancer (MIBC)

- All visible papillary disease must be fully resected (absent) prior to randomization
(residual CIS is acceptable for participants eligible for Cohorts 1, 2, and 3 only)
and documented in the electronic case report form (eCRF) at screening cystoscopy. For
participants with papillary disease only (Cohort 4), local urine cytology at screening
must be negative or atypical (for High-Grade Urothelial Carcinoma [HGUC])

- Participants must be ineligible for or have elected not to undergo radical cystectomy

- BCG-unresponsive high-risk NMIBC after treatment with adequate BCG therapy defined as
a minimum of 5 of 6 full doses of an induction course (adequate induction) plus 2 of 3
doses of a maintenance course, or at least 2 of 6 doses of a second induction course

- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Presence or history of histologically confirmed, muscle-invasive, locally advanced,
nonresectable, or metastatic urothelial carcinoma (that is, T2, T3, T4, and/or Stage
IV)

- Must not have had urothelial carcinoma or histological variant at any site outside of
the urinary bladder. Ta/T1/CIS of the upper urinary tract (including renal pelvis and
ureter) is allowable if treated with complete nephroureterectomy more than 24 months
prior to randomization

- Received a live virus vaccine within 30 days prior to the initiation of study
treatment. Inactivated (non-live or non-replicating) vaccines approved or authorized
for emergency use (for example, COVID-19) by local health authorities are allowed

- Active hepatitis B or C infection (for example, participants with history of hepatitis
C infection but undetectable hepatitis C virus polymerase chain reaction (PCR) test
and participants with history of hepatitis B infection with positive hepatitis B
surface antigen (HBsAg) antibody and undetectable PCR are allowed)

- Prior therapy with an anti-programmed-cell death 1 (PD-1), anti-PD-ligand 2 (L2)
agent, or with an agent directed to another co-inhibitory T-cell receptor

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
2/07/2027
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
Eastern Health Research - Box Hill
Recruitment hospital [3] 0 0
Macquarie University Hospital - Sydney
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
2109 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Belgium
State/province [15] 0 0
Assebroek
Country [16] 0 0
Belgium
State/province [16] 0 0
Brugge
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussel
Country [18] 0 0
Belgium
State/province [18] 0 0
Gent
Country [19] 0 0
Belgium
State/province [19] 0 0
Roeselare
Country [20] 0 0
Belgium
State/province [20] 0 0
Sint-Niklaas
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Ontario
Country [23] 0 0
Canada
State/province [23] 0 0
Quebec
Country [24] 0 0
France
State/province [24] 0 0
Bordeaux
Country [25] 0 0
France
State/province [25] 0 0
Grenoble
Country [26] 0 0
France
State/province [26] 0 0
Hyeres
Country [27] 0 0
France
State/province [27] 0 0
Limoges
Country [28] 0 0
France
State/province [28] 0 0
Lyon Cedex 03
Country [29] 0 0
France
State/province [29] 0 0
Marseille
Country [30] 0 0
France
State/province [30] 0 0
Montpellier
Country [31] 0 0
France
State/province [31] 0 0
Nimes
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 13
Country [33] 0 0
France
State/province [33] 0 0
Paris
Country [34] 0 0
France
State/province [34] 0 0
Quint-Fonsegrives
Country [35] 0 0
France
State/province [35] 0 0
Rennes cedex 9
Country [36] 0 0
France
State/province [36] 0 0
Saint Gregoire
Country [37] 0 0
France
State/province [37] 0 0
Strasbourg
Country [38] 0 0
France
State/province [38] 0 0
Suresnes
Country [39] 0 0
France
State/province [39] 0 0
Toulouse
Country [40] 0 0
Germany
State/province [40] 0 0
Duisburg
Country [41] 0 0
Germany
State/province [41] 0 0
Herne
Country [42] 0 0
Germany
State/province [42] 0 0
Köln
Country [43] 0 0
Germany
State/province [43] 0 0
Markkleeberg
Country [44] 0 0
Germany
State/province [44] 0 0
Mettmann
Country [45] 0 0
Germany
State/province [45] 0 0
Münster
Country [46] 0 0
Germany
State/province [46] 0 0
Nürnberg
Country [47] 0 0
Germany
State/province [47] 0 0
Nürtingen
Country [48] 0 0
Germany
State/province [48] 0 0
Würselen
Country [49] 0 0
Greece
State/province [49] 0 0
Holargos
Country [50] 0 0
Greece
State/province [50] 0 0
Maroussi
Country [51] 0 0
Greece
State/province [51] 0 0
Thessaloniki
Country [52] 0 0
Italy
State/province [52] 0 0
Firenze
Country [53] 0 0
Italy
State/province [53] 0 0
Genova
Country [54] 0 0
Italy
State/province [54] 0 0
Milan
Country [55] 0 0
Italy
State/province [55] 0 0
Pisa
Country [56] 0 0
Italy
State/province [56] 0 0
Roma
Country [57] 0 0
Italy
State/province [57] 0 0
Rome
Country [58] 0 0
Italy
State/province [58] 0 0
Torino
Country [59] 0 0
Italy
State/province [59] 0 0
Varese
Country [60] 0 0
Italy
State/province [60] 0 0
Vicenza
Country [61] 0 0
Japan
State/province [61] 0 0
Iizuka
Country [62] 0 0
Japan
State/province [62] 0 0
Kanagawa
Country [63] 0 0
Japan
State/province [63] 0 0
Kashihara-shi
Country [64] 0 0
Japan
State/province [64] 0 0
Kisarazu-shi
Country [65] 0 0
Japan
State/province [65] 0 0
Nagasaki-shi
Country [66] 0 0
Japan
State/province [66] 0 0
Osaka
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo
Country [68] 0 0
Japan
State/province [68] 0 0
Toyama-shi
Country [69] 0 0
Japan
State/province [69] 0 0
Toyoake
Country [70] 0 0
Japan
State/province [70] 0 0
Tsukuba-Shi
Country [71] 0 0
Japan
State/province [71] 0 0
Yokohama
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Busan
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Daegu
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Goyang-si
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Gwangju
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Seoul
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Yangsan Si
Country [78] 0 0
Netherlands
State/province [78] 0 0
Amsterdam
Country [79] 0 0
Netherlands
State/province [79] 0 0
Eindhoven
Country [80] 0 0
Netherlands
State/province [80] 0 0
Nijmegen
Country [81] 0 0
Netherlands
State/province [81] 0 0
Utrecht
Country [82] 0 0
Portugal
State/province [82] 0 0
Almada
Country [83] 0 0
Portugal
State/province [83] 0 0
Aveiro
Country [84] 0 0
Portugal
State/province [84] 0 0
Guimarães
Country [85] 0 0
Portugal
State/province [85] 0 0
Lisboa
Country [86] 0 0
Portugal
State/province [86] 0 0
Lisbon
Country [87] 0 0
Portugal
State/province [87] 0 0
Loures
Country [88] 0 0
Portugal
State/province [88] 0 0
Porto
Country [89] 0 0
Portugal
State/province [89] 0 0
Vila Nova de Gaia
Country [90] 0 0
Portugal
State/province [90] 0 0
Vila Real
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Moscow
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Nizhny Novgorod
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Novosibirsk
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Obninsk
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Omsk
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Pyatigorsk
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Saratov
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Tyumen
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Ufa
Country [100] 0 0
Spain
State/province [100] 0 0
A Coruña
Country [101] 0 0
Spain
State/province [101] 0 0
Badalona
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Cadiz
Country [104] 0 0
Spain
State/province [104] 0 0
Granada
Country [105] 0 0
Spain
State/province [105] 0 0
Jerez De La Frontera
Country [106] 0 0
Spain
State/province [106] 0 0
Madrid
Country [107] 0 0
Spain
State/province [107] 0 0
Málaga
Country [108] 0 0
Spain
State/province [108] 0 0
Sabadell
Country [109] 0 0
Spain
State/province [109] 0 0
Valencia
Country [110] 0 0
Ukraine
State/province [110] 0 0
Chernihiv
Country [111] 0 0
Ukraine
State/province [111] 0 0
Kiev
Country [112] 0 0
Ukraine
State/province [112] 0 0
Sumy
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Glasgow
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Leeds

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the overall complete response (CR) rate in
participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone
(Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without
concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in
participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04640623
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04640623